BBNX Stock May Gain From Abbott Deal to Advance iLet Integration

Key Takeaways Beta Bionics is set to integrate its iLet system with Abbott's dual glucose-ketone sensor in the U.S. The BBNX-ABT partnership combines AI insulin dosing with advanced metabolic monitoring features. BBNX aims to boost the AID market share and improve DKA detection through the new sensor integration.Beta Bionics, Inc. (BBNX) recently entered into a strategic agreement with Abbott Laboratories (ABT) to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's upc ...